Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib vs TAS-102 in Metastatic Colorectal Carcinoma
NCT03909724Phase 3Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sunitinib in colorectal cancer (CRC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Progression Free Survival at 1 year. Status: unknown.
02
Drugs
sunitinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03909724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909724.